Inhibitory effects of c-erbB-2 antisense oligonucleotide transfection on uterine endometrial cancer Ishikawa cell lines

European Journal of Gynaecological Oncology

Volumn 30, Issue 1, 2009, Pages 54-59

  Zhao, Fu Jie ^a,b   Zhang, S L ^a   Ma, L ^a   Gao, H ^a   Zong, Z H ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Natural Science Foundation of Liao Ning Province   (China)

Author keywords

Antisense; Oligonucleotides; Transfection; Uterine endometrial neoplasms

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOFECTAMINE; MESSENGER RNA; PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE; PHOSPHOROTHIOATE SCRAMBLED EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTISENSE OLIGONUCLEOTIDE; RIBONUCLEASE H; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; ONCOGENE C ERBB 2; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TARGET CELL DESTRUCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GENE THERAPY; GENES, ERBB-2; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; THIONUCLEOTIDES; TRANSFECTION;

EID: 60749109793     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yang S.P., Song S.T., Song H.F.: "Advancement of antisense oligonucleotide in treatment of breast cancer". Acta Pharmacol. Sin., 2003, 24, 289.
2. Liebhaber S.A.: "mRNA stability and the control of gene expression". Nucliec Acid Symp Ser., 1997, 36, 29.
3. Zhu Y.G., Zhou G.S., Chen Z.Z., Chen X.C.: "Cationic lipids enhanced cellular uptake and activity of bcl-2 antisense oligodeoxynucleotide G3139 in HL-60 cells". Acta Pharmacol. Sin., 2001, 22, 1007.
4. Yuan S.J., Tang ZM., Song H.F., Zhu B.Z,: "Combination of antisense oligodeoxynucleotides against C-raf and PKC-α mRNA enhancing inhibition on the proliferation of A549 cell in vitro". Chin. J. Pharmacol. Toxicol., 2000, 14, 136.
5. Cirisano F.D., Karlan B.Y.: "The role of the HER-2/neu oncogene in gynecologic cancer". J. Soc. Gynecol. Invest., 1996, 3, 99.
6. Rait A.S., Pirollo K.F., Rait V., Krygier J.E., Xiang L., Chang E.H.: "Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer". Cancer Gene Ther., 2001, 8, 728.
7. Tanabe K., Kim R., Inoue H., Emi M., Uchida Y., Toge T.: "Antisense bcl-2 and HER-2 oligonucleo- tide treatment of breast cancer cells enhances their sensitivity to anticancer drugs". Int J. Oncol., 2003, 22, 875.
8. Trost T.M., Lausch E.U., Fees S.A., Schmitt S., Enklaar T., Reutzel D.: "Premature senescence is a primary fail-safe mechanism of ERBB-2-driven tumorigenesis in breast carcinoma cells". Cancer Res., 2005, 65, 840.
9. Rait A.S., Pirollo K.F., Xiang L., Ulick D., Chang E.H.: "Tumor targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 level". Mol. Med., 2002, 8, 475.
10. Pack S.D., Alper O.M., Stromberg K., Augustus M., Ozdemirli M., Miermont A.M. et al.: "Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line". Cancer Res., 2004, 64, 789.
11. Wu Y.Z., Ren Q.L., Li S.L.: "Therapeutic effects of c-erbB-2 and c-raf-1 gene combined with antisense oligodeoxynucleotide on the human ovarian carcinoma transplanted subcutaneously in nude mice". Ai Zheng (Chin.), 2003, 22, 836.
12. Fei R., Shaoyang L.: "Combination antigene therapy targeting c-myc and c-erbB-2 in the ovarian cancer COC (1) cell line". Gynecol. Oncol., 2002, 85, 40.
13. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., Podratz K.C.: "HER-2/neu expression: a major prognostic factor in endometrial cancer". Gynecol. Oncol., 1992, 47, 179.
14. Bigsby K.M., Li A.X., Bomalaski J., Stehman F.B., Look K.Y., Sutton G.P.: "Immunohistochemical study of HER-2/neu epidermal growth factor receptor and steroid receptor expression in normal and malignant endometrium". Obstet. Gynecol., 1992, 79, 95.
15. Berchuck A., Rodriguez G., Kinny R.B., Soper J.T., Dodge R.K., Clarke-Pearson D.L. et al.: "Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease". Am. J. Obstet. Gynecol., 1991, 164, 15.
16. Yao D., Li L., Tang B., Yao Z., Chen L.: "C-erbB-2 oncoprotein expression in endometrial carcinoma and its relationship to clinical course and prognosis". J. Clin. Oncol. (China), 1997, 2, 12.
17. Saffari B., Jones L.A., el-Naggar A., Felix J.C., George J., Press M.F.: "Amplification and overexpression of HER-2/neu(c-erbB-2) in endometrial cancers: correlation with overall survival". Cancer Res., 1995, 55, 5693.
18. Rolitsky C.D., Theil K.S., McGaughy V.R., Copeland L.J., Niemann T.H.: "HER-2/neu amplification and overexpression in endometrial carcinoma". Int. J Gynecol. Pathol., 1999, 18, 138.
19. Rasty G., Murray R., Lu L., Kubilis P., Benrubi G., Masood S.: "Expresion of HER-2/neu oncogene in normal, hyperplastic and malignant endometrium". Ann. Clin. Lab. Sci., 1998, 28, 138.
20. Kohlberger P., Loesch A., Koelbl H., Breitenecker G., Kainz C., Gitsch G.: "Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer". Cancer Lett., 1996, 98, 151.
21. Kanaya S., Ikehara M.: "Functions and structures of ribonuclease H enzymes". Subcell Biochem., 1995 24, 377.
22. Lima W.F., Brown-Driver V., Fox M., Hanecak R., Bruice T.W.: "Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity". J. Biol. Chem., 1997, 272, 626.
23. Stein C.A., Cheng Y.C.: "Antisense oligonucleotides as therapeutic agents is the bullet really magical?". Science, 1993, 261, 1004.
24. Kunamaru T., Takagi T., Takakura Y., Hashida M.: "Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes". J. Drug Target., 1998, 5, 235.
25. Magin-Lachmann C., Kotzamanis G., D'Aiuto L., Cooke H., Huxley C., Wagner E.: "In vitro and in vivo delivery of intact BAC DNA-comparison of different methods". J. Gene Med., 2004, 6, 195.
26. Magin-Lachmann C., Kotzamanis G., D'Aiuto L., Wagner E., Huxley C.: "Retrofitting BACs with G418 resistance, luciferase, and oriP and EBNA-1-new vectors for in vitro and in vivo delivery". BMC Biotechnol., 2003, 3, 2.
27. Ohki E.C., Tilkins M.L., Ciccarone V.C.: "Improving the transfection efficiency of post-mitotic neurons". J. Neurosci. Methods, 2001, 112, 95.